Form 4: Tenet Healthcare Director Reports Routine Stock Transactions, Including RSU Vesting and Partial Share Sale

Tenet Healthcare Corp. Director Meghan Fitzgerald reported the vesting of restricted stock units and the subsequent sale of a portion of the resulting common stock, alongside a new RSU grant.

Summary

• Meghan Fitzgerald, a Director at Tenet Healthcare Corp (THC), reported transactions involving the company's common stock and restricted stock units (RSUs) in a recent SEC Form 4 filing.
• On May 23, 2025, Ms. Fitzgerald acquired 1,551 shares of THC common stock through the vesting of previously granted restricted stock units.
• Concurrently, on May 23, 2025, she disposed of 573 shares of THC common stock at a price of $161.33 per share.
• Following these transactions, Ms. Fitzgerald's direct beneficial ownership of THC common stock stands at 16,247 shares.
• On May 22, 2025, Ms. Fitzgerald was granted an additional 1,333 restricted stock units, which are scheduled to vest on May 22, 2026.
• The previously vested RSUs were settled with 37% in cash and 63% in shares of THC common stock.
• For the newly granted RSUs, Ms. Fitzgerald retains the option to receive up to 37% in cash upon vesting.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The filing reports routine insider transactions involving the vesting of equity compensation and a partial sale of shares, which is a common occurrence for directors. A new RSU grant also indicates ongoing compensation.

Positives

• Grant of 1,333 new Restricted Stock Units (RSUs) to Director Meghan Fitzgerald, aligning her interests with shareholder value.
• The vesting of 1,551 previously granted RSUs demonstrates the realization of prior equity compensation.

Negatives

• Sale of 573 shares of common stock by a Director, which reduces direct ownership.

Risks

• No specific risks related to company operations or financial health are disclosed in this insider transaction report.

Future Outlook

This Form 4 filing details past and future vesting schedules for equity compensation but does not provide broader forward-looking statements or guidance regarding the company's financial performance or strategic outlook.

Industry Context

This filing is a routine insider transaction report specific to a director's equity compensation and does not provide information relevant to broader industry trends or competitive dynamics within the healthcare sector.

Stakeholder Impact

• Shareholders: The sale of shares by a director could be perceived as a slight negative, but the overall impact is likely minimal given the routine nature of the transaction and the relatively small number of shares sold compared to the company's total outstanding shares. The new RSU grant aligns director interests with long-term shareholder value.
• Employees, Customers, Suppliers, Creditors: This insider transaction report has no direct or material impact on these stakeholder groups.

Next Steps

• The 1,333 Restricted Stock Units granted on May 22, 2025, are scheduled to vest on May 22, 2026.

Key Dates

Keywords

Tenet Healthcare, THC, SEC Form 4, Insider Trading, Stock Transaction, Restricted Stock Units, RSU, Common Stock, Director, Equity Compensation, Share Sale, Beneficial Ownership